Even though derivatives of erastin have been developed recently with a much greater potency to inhibit SLC7A11 (IC50 values in the low-nanomolar range) [79], niclosamide may have an advantage in terms of therapeutic use for cancer therapy because of its feature as an already FDA-approved drug that has been in use in humans for several decades. The gene discussed is SLC7A11; the disease is cancer.